3) B cell malignancies
B细胞恶性肿瘤
1.
Measurement and clinical significance of B lymphocyte stimulators level in peripheral blood plasma from patients with B cell malignancies;
B细胞恶性肿瘤患者外周血浆B细胞刺激因子水平测定及临床意义
2.
This article reviews the progress of Blys and its receptor about their molecular structure,biologic activity and their relationship with pathogenesy of B cell malignancies.
本文就Blys及其受体的分子结构、生物学活性及其与B细胞恶性肿瘤发病之间的关系的研究进展进行综述。
4) Large B Cell/Diffuse
大B细胞/弥漫性
5) CD20 positive B cell
CD20阳性B细胞
1.
The biologic distribution and clearances of 131I -rituximab in 13 CD20 positive B cell NHL(non-Hodgkin s lymphoma, NHL) patients are detected by plane scans, and the whole-body counts are collected for drawing time-radioactivity curve, based on which the whole body clearance rate(A) and the whole-body effective half life(Teff)of each patientareare obtained.
选取CD20阳性B细胞NHL患者13例,于不同时相行全身平面显像,监测131I-美罗华的全身分布和清除情况,绘制时间-放射性曲线得到全身清除速率常数(λ),计算全身有效半清除时间Teff,采用医用内照射吸收剂量(Medical Internal Radiation Dosimetry,MIRD)法求得示踪剂量水平的全身辐射吸收剂量,并参照体重为70 kg的标准人体模型131I-美罗华全身最大耐受剂量为75 cGy,求得个体化的最大允许注射活度。
补充资料:大红细胞性贫血
大红细胞性贫血
〖HT5”SS〗〖JP2〗macrocytic anemia〖JP〗
即“巨幼红细胞性贫血”。
说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条